期刊
BONE MARROW TRANSPLANTATION
卷 56, 期 7, 页码 1683-1690出版社
SPRINGERNATURE
DOI: 10.1038/s41409-021-01219-8
关键词
-
资金
- ASCO/CCF/FLASCO Young Investigator Award
Higher infused total nucleated cell dose in allogeneic bone marrow transplant with post-transplant cyclophosphamide is associated with improved overall survival. The study suggests that infused CD34+ cell doses >= 5 x 10(6) cells/kg may result in improved survival in patients receiving allogeneic PBSCT with PTCy. Targeting a CD34+ cell dose of >= 5 x 10(6) cells/kg for allogeneic PBSCT with PTCy is supported by these findings.
Higher infused total nucleated cell dose (TNC) in allogeneic bone marrow transplant (BMT) with post-transplant cyclophosphamide (PTCy) is associated with improved overall survival. As many centers prefer peripheral blood stem cell grafts (PBSCT) with PTCy, the effect of cell dose on outcomes with this platform also requires elucidation. We retrospectively evaluated 144 consecutive adult patients who received allogeneic T-cell replete PBSCT with PTCy-based graft-versus-host disease (GVHD) prophylaxis for a hematologic malignancy from 2012-2018. The infused CD34+ cell dose was stratified into low (<5 x 10(6)/kg), intermediate (5-10 x 10(6)/kg) and high (>10 x 10(6)/kg) dose level groups. In multivariate analysis, the low CD34+ cell dose group had worse non-relapse mortality (HR = 4.51, 95% CI: 1.92-10.58, p < 0.001), progression- free survival (HR = 4.11, 95% CI: 2.07-8.15, p < 0.001), and overall survival (HR = 4.06, 95% CI: 2.00-8.25, p <= 0.001) compared to the intermediate group. Clinical outcomes between the intermediate and high CD34+ cell dose groups were similar. TNC and CD3+ cell dose had no significant impacts on outcomes. These findings suggest that, in patients receiving allogeneic PBSCT with PTCy, infused CD34+ cell doses >= 5 x 10(6) cells/kg may result in improved survival. Thus, this study supports targeting a CD34+ cell dose of >= 5 x 10(6) cells/kg for allogeneic PBSCT with PTCy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据